The collaboration marks a turning point in AI-driven drug design and trial forecasting, de-risking the drug development ...

The pharmaceutical industry is undergoing a profound transformation thanks to artificial intelligence (AI). While drug development has traditionally taken ten years or longer and cost billions of ...

Predictive AI modeling startup and biotech-focused venture fund unite to accelerate next-generation therapeutics and reshape the FDA regulatory path. Together with QNova, we’re using AI to help ...

Nvidia and Eli Lilly are teaming up on a $1 billion AI-powered lab to accelerate drug discovery, combining robotics, molecular modeling and automated research workflows.

Phase III is intended to generate meaningful biological data on potential drug compounds prioritized by YuvaBio’s classifier, which applies proprietary machine-learning methods to identify candidates ...

Recursion Pharmaceuticals RXRX is redefining the traditional model of drug discovery by harnessing the power of artificial intelligence (AI) through its proprietary RecursionOS platform, developed in ...

Insilico Medicine (3696.HK), a clinical-stage drug discovery and development company driven by generative artificial intelligence (AI), is successfully listed on the Hong Kong Stock Exchange today, ...

Bissan Al-Lazikani (left) is a Professor of Genomic Medicine and Director of Therapeutics Data Science at The University of Texas MD Anderson Cancer Center (Houston, TX, USA), where she heads an ...